Go Pro
→ SpaceX pays a 10X launch penalty (From Freedom Financial) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Alector, Inc. stock logo
ALEC
Alector
$2.07
-1.2%		$1.68
$1.09
▼
$3.40
$231.69M0.6829,099 shs101,164 shs
Immunovant, Inc. stock logo
IMVT
Immunovant
$41.69
+1.9%		$37.57
$14.47
▼
$41.93
$8.61B0.771.54 million shs103,068 shs
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
$330.23
+1.0%		$342.73
$136.73
▼
$382.54
$9.79B0.53347,016 shs13,411 shs
Ocugen, Inc. stock logo
OCGN
Ocugen
$1.38
+0.4%		$1.34
$0.98
▼
$2.73
$466.28M2.217.32 million shs602,550 shs
REGENXBIO Inc. stock logo
RGNX
REGENXBIO
$10.98
+3.1%		$10.17
$5.45
▼
$16.19
$567.51M0.941.44 million shs51,546 shs
7 Stocks That Could Lead the Next Market Boom Cover
7 Stocks That Could Lead the Next Market Boom

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Alector, Inc. stock logo
ALEC
Alector
+23.67%+35.71%+29.81%-2.79%-6.28%
Immunovant, Inc. stock logo
IMVT
Immunovant
+2.61%+3.99%+3.07%+39.93%+177.30%
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
-1.37%+0.70%-10.60%+4.63%+137.79%
Ocugen, Inc. stock logo
OCGN
Ocugen
+4.58%+4.58%-6.80%-6.80%+39.70%
REGENXBIO Inc. stock logo
RGNX
REGENXBIO
+2.21%+3.40%-23.66%+6.08%+42.76%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Alector, Inc. stock logo
ALEC
Alector
$2.07
-1.2%		$1.68
$1.09
▼
$3.40
$231.69M0.6829,099 shs101,164 shs
Immunovant, Inc. stock logo
IMVT
Immunovant
$41.69
+1.9%		$37.57
$14.47
▼
$41.93
$8.61B0.771.54 million shs103,068 shs
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
$330.23
+1.0%		$342.73
$136.73
▼
$382.54
$9.79B0.53347,016 shs13,411 shs
Ocugen, Inc. stock logo
OCGN
Ocugen
$1.38
+0.4%		$1.34
$0.98
▼
$2.73
$466.28M2.217.32 million shs602,550 shs
REGENXBIO Inc. stock logo
RGNX
REGENXBIO
$10.98
+3.1%		$10.17
$5.45
▼
$16.19
$567.51M0.941.44 million shs51,546 shs
7 Stocks That Could Lead the Next Market Boom Cover
7 Stocks That Could Lead the Next Market Boom

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Alector, Inc. stock logo
ALEC
Alector
+23.67%+35.71%+29.81%-2.79%-6.28%
Immunovant, Inc. stock logo
IMVT
Immunovant
+2.61%+3.99%+3.07%+39.93%+177.30%
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
-1.37%+0.70%-10.60%+4.63%+137.79%
Ocugen, Inc. stock logo
OCGN
Ocugen
+4.58%+4.58%-6.80%-6.80%+39.70%
REGENXBIO Inc. stock logo
RGNX
REGENXBIO
+2.21%+3.40%-23.66%+6.08%+42.76%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Alector, Inc. stock logo
ALEC
Alector
2.13
Hold$3.6375.54% Upside
Immunovant, Inc. stock logo
IMVT
Immunovant
2.50
Moderate Buy$44.005.54% Upside
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
2.92
Moderate Buy$361.569.49% Upside
Ocugen, Inc. stock logo
OCGN
Ocugen
2.60
Moderate Buy$9.50590.91% Upside
REGENXBIO Inc. stock logo
RGNX
REGENXBIO
2.54
Moderate Buy$23.73116.04% Upside

Current Analyst Ratings Breakdown

Latest ALEC, RGNX, KRYS, IMVT, and OCGN Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/10/2026
REGENXBIO Inc. stock logo
RGNX
REGENXBIO
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetBuy$26.00 ➝ $23.00
8/7/2026
REGENXBIO Inc. stock logo
RGNX
REGENXBIO
Morgan Stanley logo
Morgan Stanley
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOverweight$18.00
8/7/2026
REGENXBIO Inc. stock logo
RGNX
REGENXBIO
Barclays PLC logo
Barclays
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeOverweight ➝ Hold
8/7/2026
REGENXBIO Inc. stock logo
RGNX
REGENXBIO
Barclays PLC logo
Barclays
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOverweight ➝ Equal Weight$12.00
8/4/2026
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
Citigroup Inc. logo
Citigroup
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$378.00 ➝ $386.00
8/4/2026
Immunovant, Inc. stock logo
IMVT
Immunovant
JPMorgan Chase & Co. logo
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOverweight$47.00 ➝ $50.00
8/3/2026
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeBuy (B-) ➝ Buy (B)
8/3/2026
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
Chardan Capital logo
Chardan Capital
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeStrong-Buy
7/31/2026
Alector, Inc. stock logo
ALEC
Alector
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
7/29/2026
Immunovant, Inc. stock logo
IMVT
Immunovant
Sanford C. Bernstein logo
Sanford C. Bernstein
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeHold
7/14/2026
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
Bank of America Corporation logo
Bank of America
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$364.00 ➝ $396.00
(Data available from 8/12/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Alector, Inc. stock logo
ALEC
Alector
$13.86M16.63N/AN/A($0.09) per share-22.94
Immunovant, Inc. stock logo
IMVT
Immunovant
N/AN/AN/AN/A$3.56 per shareN/A
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
$440.48M22.19$7.26 per share45.49$45.92 per share7.19
Ocugen, Inc. stock logo
OCGN
Ocugen
$4.58M101.78N/AN/A($0.05) per share-27.50
REGENXBIO Inc. stock logo
RGNX
REGENXBIO
$170.44M3.33N/AN/A$1.39 per share7.90
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Alector, Inc. stock logo
ALEC
Alector
-$142.93M-$1.10N/AN/AN/A-850.13%-531.03%-44.00%N/A
Immunovant, Inc. stock logo
IMVT
Immunovant
-$505.61M-$2.82N/AN/AN/AN/A-69.59%-62.49%N/A
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
$204.83M$7.9841.4735.39N/A54.82%19.34%17.65%N/A
Ocugen, Inc. stock logo
OCGN
Ocugen
-$67.85M-$0.26N/AN/AN/AN/A-127,987.80%-115.95%N/A
REGENXBIO Inc. stock logo
RGNX
REGENXBIO
-$193.88M-$3.79N/AN/AN/A-112.58%-220.07%-46.04%N/A

Latest ALEC, RGNX, KRYS, IMVT, and OCGN Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/6/2026Q2 2026
Alector, Inc. stock logo
ALEC
Alector
-$0.2286-$0.21+$0.0186-$0.21$1.71 million$3.32 million
8/6/2026Q1 2027
Immunovant, Inc. stock logo
IMVT
Immunovant
-$0.6289-$0.75-$0.1211-$0.75$7.10 million$7.10 million
8/6/2026Q2 2026
Ocugen, Inc. stock logo
OCGN
Ocugen
-$0.0533-$0.07-$0.0167-$0.07$0.89 million$1.49 million
8/6/2026Q2 2026
REGENXBIO Inc. stock logo
RGNX
REGENXBIO
$0.0787$0.43+$0.3513$0.43$97.63 million$108.02 million
8/3/2026Q2 2026
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
$1.70$1.79+$0.09$1.79$120.93 million$119.22 million
5/20/2026Q4 2026
Immunovant, Inc. stock logo
IMVT
Immunovant
-$0.60-$0.73-$0.13-$0.73N/AN/A
5/14/2026Q1 2026
REGENXBIO Inc. stock logo
RGNX
REGENXBIO
-$1.36-$1.72-$0.36-$1.72$25.84 million$6.39 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Alector, Inc. stock logo
ALEC
Alector
N/AN/AN/AN/AN/A
Immunovant, Inc. stock logo
IMVT
Immunovant
N/AN/AN/AN/AN/A
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
N/AN/AN/AN/AN/A
Ocugen, Inc. stock logo
OCGN
Ocugen
N/AN/AN/AN/AN/A
REGENXBIO Inc. stock logo
RGNX
REGENXBIO
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Alector, Inc. stock logo
ALEC
Alector
0.80
5.26
5.26
Immunovant, Inc. stock logo
IMVT
Immunovant
N/A
7.27
7.27
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
N/A
8.32
7.96
Ocugen, Inc. stock logo
OCGN
Ocugen
4.17
0.80
0.80
REGENXBIO Inc. stock logo
RGNX
REGENXBIO
N/A
2.86
2.86

Institutional Ownership

CompanyInstitutional Ownership
Alector, Inc. stock logo
ALEC
Alector
85.83%
Immunovant, Inc. stock logo
IMVT
Immunovant
47.08%
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
86.29%
Ocugen, Inc. stock logo
OCGN
Ocugen
10.27%
REGENXBIO Inc. stock logo
RGNX
REGENXBIO
88.08%

Insider Ownership

CompanyInsider Ownership
Alector, Inc. stock logo
ALEC
Alector
8.30%
Immunovant, Inc. stock logo
IMVT
Immunovant
1.90%
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
13.10%
Ocugen, Inc. stock logo
OCGN
Ocugen
3.95%
REGENXBIO Inc. stock logo
RGNX
REGENXBIO
14.22%
CompanyEmployeesShares OutstandingFree FloatOptionable
Alector, Inc. stock logo
ALEC
Alector
270111.66 million102.39 millionOptionable
Immunovant, Inc. stock logo
IMVT
Immunovant
120206.55 million202.63 millionOptionable
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
21029.60 million25.72 millionOptionable
Ocugen, Inc. stock logo
OCGN
Ocugen
80339.11 million325.72 millionOptionable
REGENXBIO Inc. stock logo
RGNX
REGENXBIO
37051.70 million44.35 millionOptionable

Recent News About These Companies

HC Wainwright Has Pessimistic View of REGENXBIO Q3 Earnings
 |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/hc-wainwright-has-pessimistic-view-of-regenxbio-q3-earnings-2026-08-12/
Regenxbio's Multi-Catalyst Setup Is Hard To Ignore (Rating Upgrade)
August 11 at 3:00 PM  |  seekingalpha.comhttps://seekingalpha.com/article/4934891-regenxbios-multi-catalyst-setup-is-hard-to-ignore-rating-upgrade
Dimensional Fund Advisors LP Increases Stock Position in REGENXBIO Inc. $RGNX
August 10 at 3:28 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-dimensional-fund-advisors-lp-increases-stock-position-in-regenxbio-inc-rgnx-2026-08-10/
REGENXBIO's (RGNX) "Equal Weight" Rating Reiterated at Barclays
August 10 at 2:24 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30951730
Regenxbio Seen on Track for Duchenne Approval as Data Strengthens, RBC Says
August 8, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/regenxbio-seen-track-duchenne-approval-173623902.html
REGENXBIO (NASDAQ:RGNX) Upgraded at Wall Street Zen
August 8, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30947612
REGENXBIO (NASDAQ:RGNX) Rating Increased to Hold at Wall Street Zen
August 8, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/regenxbio-nasdaqrgnx-rating-increased-to-hold-at-wall-street-zen-2026-08-08/
REGENXBIO (NASDAQ:RGNX) Shares Down 6.1% - Here's Why
August 7, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/regenxbio-nasdaqrgnx-shares-down-61-heres-why-2026-08-07/
Barclays Reiterates "Equal Weight" Rating for REGENXBIO (NASDAQ:RGNX)
August 7, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/barclays-reiterates-equal-weight-rating-for-regenxbio-nasdaqrgnx-2026-08-07/
REGENXBIO Q2 Earnings Call Highlights
August 7, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/regenxbio-q2-earnings-call-highlights-2026-08-07/
REGENXBIO (NASDAQ:RGNX) Issues Earnings Results, Beats Expectations By $0.35 EPS
August 6, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/regenxbio-nasdaqrgnx-issues-earnings-results-beats-expectations-by-035-eps-2026-08-06/
Regenxbio outlines cash runway into Q4 2027 as RGX-202 targets module 1 BLA filing in Q3 2026
August 6, 2026  |  seekingalpha.comhttps://seekingalpha.com/news/4628565-regenxbio-outlines-cash-runway-into-q4-2027-as-rgxminus-202-targets-module-1-bla-filing-in-q3
REGENXBIO Inc. (RGNX) Q2 2026 Earnings Call Transcript
August 6, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4932432-regenxbio-inc-rgnx-q2-2026-earnings-call-transcript
Regenxbio (RGNX) Beats Q2 Earnings and Revenue Estimates
August 6, 2026  |  zacks.comhttps://www.zacks.com/stock/news/2969874/regenxbio-rgnx-beats-q2-earnings-and-revenue-estimates?cid=cs-stocknewsapi-ft-fundamental_analysis|yseop_template_4-2969874
Regenxbio: Q2 Earnings Snapshot
August 6, 2026  |  stamfordadvocate.comS
REGENXBIO Reports Second Quarter 2026 Financial Results and Operational Highlights
August 6, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/regenxbio-reports-second-quarter-2026-financial-results-and-operational-highlights-302844662.html
REGENXBIO Inc. (NASDAQ:RGNX) Given Consensus Recommendation of "Moderate Buy" by Brokerages
August 4, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30939333
REGENXBIO Inc. (NASDAQ:RGNX) Receives Average Rating of "Moderate Buy" from Analysts
August 4, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/regenxbio-inc-nasdaqrgnx-receives-average-rating-of-moderate-buy-from-analysts-2026-08-04/
REGENXBIO to Host Conference Call on August 6 to Discuss Second Quarter 2026 Financial Results and Operational Highlights
August 3, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/regenxbio-to-host-conference-call-on-august-6-to-discuss-second-quarter-2026-financial-results-and-operational-highlights-302840354.html
REGENXBIO (RGNX) Projected to Post Earnings on Thursday
July 30, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/regenxbio-rgnx-projected-to-post-earnings-on-thursday-2026-07-30/
New Strong Sell Stocks for July 23rd
July 23, 2026  |  zacks.comhttps://www.zacks.com/stock/news/2958803/new-strong-sell-stocks-for-july-23rd?cid=cs-stocknewsapi-ft-tale_of_the_tape|new_zacks_5_rank_stocks-2958803

New MarketBeat Followers Over Time

Media Sentiment Over Time

Alector stock logo

Alector NASDAQ:ALEC

$2.06 -0.03 (-1.20%)
As of 10:27 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, an immune activity in the brain with genetic links to multiple neurodegenerative disorders, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. The company also offers AL002, a product candidate that is in Phase II clinical trial for the treatment of Alzheimer's disease. Alector, Inc. has a collaboration agreement with Adimab, LLC for the research and development of antibodies; and a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of monoclonal antibodies, such as AL001 and AL101 to treat neurodegenerative diseases. The company was founded in 2013 and is headquartered in South San Francisco, California.

Immunovant stock logo

Immunovant NASDAQ:IMVT

$41.69 +0.76 (+1.86%)
As of 10:27 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, and Graves diseases, as well as warm autoimmune hemolytic anemia. The company is headquartered in New York, New York. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.

Krystal Biotech stock logo

Krystal Biotech NASDAQ:KRYS

$330.22 +3.18 (+0.97%)
As of 10:27 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). The company also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.

Ocugen stock logo

Ocugen NASDAQ:OCGN

$1.38 +0.01 (+0.36%)
As of 10:27 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease. It is also involved in the development of OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration; and NeoCart, an autologous chondrocyte-derived neocartilage, currently under Phase 3 studies indicated for the repair of knee cartilage injuries in adult. In addition, the company is developing OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine. It has collaboration agreements with National Institute of Allergy and Infectious Diseases for early clinical studies for the OCU500 program; and a strategic partnership with CanSino Biologics Inc. for manufacturing its modifier gene therapy pipeline product candidates. The company was founded in 2013 and is headquartered in Malvern, Pennsylvania.

REGENXBIO stock logo

REGENXBIO NASDAQ:RGNX

$10.98 +0.33 (+3.13%)
As of 10:27 AM Eastern
This is a fair market value price provided by Massive. Learn more.

REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy. It also develops RGX-121 for the treatment of mucopolysaccharidosis type II that is in Phase III clinical trial; RGX-111 for treating mucopolysaccharidosis type I; RGX-181 for the treatment of late infantile neuronal ceroid lipofuscinosis type II; and RGX-381 to treat the ocular manifestations of CLN2 disease. In addition, the company licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies. Further, it has a collaboration and license agreement with AbbVie Global Enterprises Ltd. to develop ABBV-RGX-314 outside the United States. REGENXBIO Inc. was incorporated in 2008 and is headquartered in Rockville, Maryland.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas